<DOC>
	<DOC>NCT01689389</DOC>
	<brief_summary>The aim of the study is to describe patient characteristics (demographic and clinical) and the patterns of use of Quetiapine XR in patients receiving the drug for the first time in real-life practice regardless the final diagnosis.</brief_summary>
	<brief_title>Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study</brief_title>
	<detailed_description>Description of the use of Quetiapine Extended Release (XR) in real-life practice in France</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>New patients treated with Xeroquel XR Patients aged 18 years and over Diagnosis of bipolar disorder or schizophrenia according to DSMIV criteria Patient included in a therapeutic trial (HurietSerusclat Act) Patient refusing to participate in the study Pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Bipolar episodes</keyword>
	<keyword>France</keyword>
	<keyword>Xeroquel</keyword>
	<keyword>Real-life</keyword>
</DOC>